Search company, investor...

Oramed Pharmaceuticals

oramed.com

Founded Year

2006

Market Cap

0.33B

Stock Price

8.37

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (NASDAQ: ORMP) develops an oral drug delivery technology, including insulin, that allows for the oral delivery of drugs presently administered only via injection.

Headquarters Location

1185 Avenue of the Americas 3rd Floor

New York, New York, 10036,

United States

Missing: Oramed Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oramed Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Oramed Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oramed Pharmaceuticals is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,898 items

Oramed Pharmaceuticals Patents

Oramed Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Diabetes
  • G protein coupled receptors
  • Fluoroarenes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/23/2020

7/26/2022

Diabetes, Peptide hormones, Piperidines, G protein coupled receptors, Fluoroarenes

Grant

Application Date

3/23/2020

Grant Date

7/26/2022

Title

Related Topics

Diabetes, Peptide hormones, Piperidines, G protein coupled receptors, Fluoroarenes

Status

Grant

Latest Oramed Pharmaceuticals News

08:40 ET Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Nov 29, 2022

USA - English Share this article Share this article NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled: "Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study," authored by Roy Eldor, MD PhD, Bruce H. Francis, MD, Alexander Fleming, MD, Joel Neutel, MD, Kenneth Homer, MS, Miriam Kidron, PhD, and Julio Rosenstock, MD. The article presents the results of a 12-week multicenter, randomized, placebo-controlled trial assessing the safety and efficacy of multiple active doses of Oramed's lead drug candidate ORMD-0801 in patients with uncontrolled Type 2 Diabetes (T2DM) on chronic background therapy with Metformin or combination oral therapy. The trial met the primary endpoint of statistically significant reductions of HbA1c from baseline to Week 12. In addition, the treatment doses were safe, well tolerated and not associated with weight gain or hypoglycemia. "This paper presents interesting and important results of Oramed's Phase 2 dose ranging study of oral insulin. Based on the results of this study, a bedtime dose of 8 mg is being carried forward into the Phase 3 registration studies," said Roy Eldor, MD PhD, Director, Diabetes Unit, Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center, and a member of Oramed's Scientific Advisory Board. The article can be accessed on Oramed's website under Scientific Articles and Abstracts . About Oramed Pharmaceuticals Oramed Pharmaceuticals (Nasdaq: ORMP ) (TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801 , which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule ( ORMD-0901 ). For more information, please visit www.oramed.com . Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the plans for Phase 3 registration studies, as well as the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed' s reports filed from time to time with the Securities and Exchange Commission.

Oramed Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oramed Pharmaceuticals Rank

Oramed Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Oramed Pharmaceuticals founded?

    Oramed Pharmaceuticals was founded in 2006.

  • Where is Oramed Pharmaceuticals's headquarters?

    Oramed Pharmaceuticals's headquarters is located at 1185 Avenue of the Americas, New York.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.